ICG Enhancement for Targeted Lymph Node Dissection in Axillary Staging
Abstract
Objective: Axillary lymph node dissection (ALND) has been the standard of care for breast cancer with positive axillary lymph nodes. However, recent advances have shown targeted axillary lymph node dissection (TALND) to be an oncologically safe and effective alternative in patients with adequate response to neoadjuvant therapy (NAT). Traditionally, dual mapping combined a radioactive tracer with blue dye. Our study aimed to evaluate indocyanide green (ICG) as an adjunct to increase node detection.
Methods: A retrospective review of 25 patients with biopsy-confirmed axillary lymph node metastases who underwent TALND was conducted. Prior to NAT, metastatic nodes were marked, and preoperatively, localization was achieved via radiologic guidewire placement. During surgery, the marked node was excised, and sentinel node mapping was performed using a combination of ICG fluorescence, technetium-99 radiotracer, and palpation. The number and method of node detection were analyzed.
Results: A total of 70 sentinel lymph nodes were identified across 21 patients, with a median of 3 nodes per patient (range 1–7). Of these, 28 nodes (40%) were detected exclusively with ICG, 31 (44.2%) with both ICG and radiotracer, 8 (11.4%) solely with radiotracer, and 7 (10%) with palpation. Metastatic involvement was present in 7 of 21 patients (33%), including two cases in which metastatic nodes were detected only by ICG.
Conclusion: ICG is a valuable adjunct for sentinel lymph node detection during TALND. Combined use of ICG and radiotracer enhances nodal identification and may reduce the need for extensive ALND in patients with clinically node-positive breast cancer.
Full text article
References
Caudle AS, Yang WT, Krishnamurthy S. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072-8.
Dominici LS, Neuman HB, Wong SL. Axillary management of breast cancer: A comprehensive review. JAMA Oncol. 2015;1(1):61-8.
Caudle AS, Hunt KK, Tucker SL. American College of Surgeons Oncology Group (ACOSOG) Z1071: A prospective trial to identify the false-negative rate of sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer. J Clin Oncol. 2014;32(17):1873-8.
Racz JM, Caudle AS. Sentinel lymph node surgery after neoadjuvant therapy: Principles and techniques. Ann Surg Oncol. 2019;26(10):3040-5.
Wong SL, Edwards MJ, Chao C. Sentinel lymph node biopsy for breast cancer: Impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001;192(6):684-9.
McMasters KM, Wong SL, Martin RC. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: Results of a multi-institutional study. Ann Surg. 2001;233(5):676-87.
Mayer EL, Dominici LS. Breast cancer axillary staging: Much ado about micrometastatic disease. J Clin Oncol. 2015;33(10):1095-7.
Caudle AS, Yang W, Mittendorf EA. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: A prospective feasibility trial. JAMA Surg. 2015;150(2):137-43.
Weiss A, Lin H, Babiera GV. Evolution in practice patterns of axillary management following mastectomy in patients with 1–2 positive sentinel nodes. Breast Cancer Res Treat. 2019;176(3):435-44.
Grischke EM, Röhm C, Hahn M, Helms G, Brucker S, Wallwiener D. ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial. Geburtshilfe Frauenheilkd. 2015 Sep;75(9):935-940. doi: 10.1055/s-0035-1557905. PMID: 26500370; PMCID: PMC4596694.
Jung, S.Y., et al., The Sentinel Lymph Node Biopsy Using Indocyanine Green Fluorescence Plus Radioisotope Method Compared With the Radioisotope-Only Method for Breast Cancer Patients After Neoadjuvant Chemotherapy: A Prospective, Randomized, Open-Label, Single-Center Phase 2 Trial. Ann Surg Oncol, 2019. 26(8): p. 2409-2416.
Chirappapha, P., et al., Sentinel lymph node biopsy after neoadjuvant treatment of breast cancer using blue dye, radioisotope, and indocyanine green: Prospective cohort study. Ann Med Surg (Lond), 2020. 59: p. 156-160.
Bargon, C.A., et al., Sentinel Lymph Node Mapping in Breast Cancer Patients Through Fluorescent Imaging Using Indocyanine Green: The INFLUENCE Trial. Ann Surg, 2022. 276(5): p. 913-920.
Tarapongpun, T., et al., Comparative efficacy of indocyanine green and Tc-99m for sentinel lymph node biopsy in breast cancer: Upfront surgery and post-neoadjuvant chemotherapy. Asian Journal of Surgery, 2025. 48(5): p. 2866-2873.
Pinto, C.S., et al., Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients. Breast Cancer, 2022. 29(4): p. 709-719.
Yuan, L., et al., Comparison of sentinel lymph node detection performances using blue dye in conjunction with indocyanine green or radioisotope in breast cancer patients: a prospective single-center randomized study. Cancer Biol Med, 2018. 15(4): p. 452-460.
Akrida I, Michalopoulos NV, Lagadinou M, Papadoliopoulou M, Maroulis I, Mulita F. An Updated Review on the Emerging Role of Indocyanine Green (ICG) as a Sentinel Lymph Node Tracer in Breast Cancer. Cancers (Basel). 2023;15(24):5755. Published 2023 Dec 8. doi:10.3390/cancers15245755
Yin R, Ding LY, Wei QZ, Zhou Y, Tang GY, Zhu X. Comparisons of ICG-fluorescence with conventional tracers in sentinel lymph node biopsy for patients with early-stage breast cancer: A meta-analysis. Oncol Lett. 2021;21(2):114. doi:10.3892/ol.2020.12375
Kang B, Lee JH, Lee J, et al. Comparative Study Between Radioisotope Uptake and Fluorescence Intensity of Indocyanine Green for Sentinel Lymph Node Biopsy in Breast Cancer. J Breast Cancer. 2022;25(3):244-252. doi:10.4048/jbc.2022.25.e27
Eriksson AG, Beavis A, Soslow RA, et al. A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer. Int J Gynecol Cancer. 2017;27(4):743-747. doi:10.1097/IGC.0000000000000959
Somashekhar SP, Arvind R, Kumar CR, Ahuja V, Ashwin KR. Sentinel node mapping using indocyanine green and near-infrared fluorescence imaging technology for endometrial cancer: A prospective study using a surgical algorithm in Indian patients. J Minim Access Surg. 2021;17(4):479-485. doi:10.4103/jmas.JMAS_154_20
Moore AM, Caudle AS, Sun SX, et al. Residual Nodal Burden After Neoadjuvant Chemotherapy in cN1 Breast Cancer Patients with Positive Nodes at Targeted Axillary Dissection. Ann Surg Oncol. 2024;31(11):7264-7270. doi:10.1245/s10434-024-15797-6
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.